

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06666-022002	Application No. 10/045,178
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Noriyuki Kasahara et al.	
		Filing Date January 11, 2002	Group Art Unit 1632

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/IP/	AA	6,033,902	03-07-2000	Haseltine et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
	AL						
	AM						
	AN						
	AO						
	AP						

<b>Other Documents (Include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/IP/	AQ	Jolly, Viral vector systems for gene therapy. <i>Cancer Gene Therapy</i> 1:51-64 (1994)
/IP/	AR	Miller Targeted vectors for gene therapy. <i>The FASEB Journal</i> 9:190-9 (1995)
/IP/	AS	Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy. <a href="http://www.nih.gov">www.nih.gov</a> December 1995
	AT	Verma et al., Gene therapy-promises, problems and prospects. <i>Nature</i> 389:239-242 (1997)

Examiner Signature  /Ileana Popa/	Date Considered  03/29/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	